FDA Approves First Oral COVID-19 PEP Drug, Xocova

Key Takeaways

• FDA approved Xocova for COVID-19 PEP in adults and adolescents ≥12 years after household or similar exposure, Shionogi said in a June 1, 2026 Business Wire release.
• Approval came ahead of the June 16, 2026 PDUFA action date and does not include a U.S. treatment indication for active COVID-19.
• SCORPIO-PEP (NCT05897541) showed symptomatic COVID-19 by day 10 in 2.9% on ensitrelvir versus 9.0% on placebo (RR 0.33).
• Dosing in the company announcement is a five-day oral course: three tablets on day 1 and one tablet on days 2–5.

What did the FDA approve?

The U.S. Food and Drug Administration approved Xocova (ensitrelvir) for post-exposure prophylaxis of COVID-19 in adults and adolescents 12 years of age and older following contact with an individual who has COVID-19.

According to Shionogi's June 1, 2026 Business Wire announcement, the company positions Xocova as the first and only oral option to help prevent COVID-19 after exposure in the current U.S. landscape, with approval arriving before the June 16, 2026 PDUFA date.

The same release states Xocova is approved in the United States for PEP and is not offered as a COVID-19 treatment in the U.S. market.

What evidence supported the Xocova approval?

Approval rests on SCORPIO-PEP, a global Phase 3 randomized, double-blind, placebo-controlled household-contact study.

Results published in the New England Journal of Medicine (DOI 10.1056/NEJMoa2509306) reported COVID-19 by day 10 in 2.9% of ensitrelvir recipients versus 9.0% on placebo in the modified intention-to-treat population (risk ratio 0.33; 95% CI 0.22–0.49; P<0.001), a 67% relative risk reduction.

Adverse-event rates were similar (about 15% in each arm in the company summary), with serious adverse events at 0.2% in each group and no COVID-19-related hospitalizations or deaths reported in the NEJM trial report.

How was SCORPIO-PEP designed?

The trial enrolled household contacts aged 12 years and older who screened locally SARS-CoV-2-negative and were asymptomatic at enrollment after exposure to a symptomatic household index patient.

Participants started study drug within 72 hours of index-patient symptom onset and received ensitrelvir 375 mg on day 1 then 125 mg on days 2–5, or matching placebo, as described in the NEJM paper and the company wire.

The study is registered as NCT05897541 on ClinicalTrials.gov, with primary analysis focused on contacts confirmed negative by central laboratory RT-PCR at baseline.

How does oral PEP change the COVID-19 toolkit?

Prior U.S. COVID-19 antivirals such as remdesivir (Veklury) were developed primarily as treatment, including intravenous hospital use, rather than as an at-home oral post-exposure preventive.

An oral five-day PEP regimen shifts operations toward household contacts, congregate settings, and occupational exposures where rapid pharmacy dispensing matters more than infusion capacity.

Payers and health systems will still need real-world uptake data, drug-interaction management, and clarity on vaccination status subgroups before modeling large prevention budgets.

What should BD, market access, and investors watch?

Watch formulary placement versus vaccines and monoclonal antibodies, especially for high-risk household contacts who cannot rely on timely vaccination boosters alone.

Monitor whether Shionogi later pursues a U.S. treatment indication after earlier treatment-program setbacks, and how EMA review of ensitrelvir for PEP and treatment progresses.

Track supply readiness for surge demand during seasonal waves and any FDA labeling constraints on age, timing windows, or concomitant medications.

What remains unproven after approval headlines?

U.S. approval does not mean Xocova treats symptomatic COVID-19 in American patients; company materials explicitly separate PEP from treatment for the U.S. label.

SCORPIO-PEP measured prevention through day 10 in household contacts under trial timing rules. Effectiveness outside that 72-hour start window, in non-household exposures, or against future variants is not established by the pivotal readout alone.

Long-term real-world effectiveness, adherence, and resistance patterns remain open questions for 2026–2027 surveillance.

Related NovaPharma coverage

• FDA approves Vertex Journavx for acute pain
• FDA approves lumasiran coverage
• Ensitrelvir fumaric acid drug profile

Frequently Asked Questions

Primary Sources

1. Business Wire — Shionogi announces FDA approval of XOCOVA
2. NEJM — Ensitrelvir for Covid-19 Postexposure Prophylaxis (DOI 10.1056/NEJMoa2509306)
3. ClinicalTrials.gov — SCORPIO-PEP (NCT05897541)